Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Merryman RW"'
Autor:
Merryman RW; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA., Rhoades J; Gerstner Center for Cancer Diagnostics Broad Institute Cambridge Massachusetts USA., Xiong K; Gerstner Center for Cancer Diagnostics Broad Institute Cambridge Massachusetts USA., Redd RA; Department of Data Science Dana-Farber Cancer Institute Boston Massachusetts USA., Antel K; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA.; Institute for Infectious Disease and Molecular Medicine University of Cape Town Cape Town South Africa., An HH; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA., McDonough M; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA., Guerrero L; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA., Crnjac A; Gerstner Center for Cancer Diagnostics Broad Institute Cambridge Massachusetts USA., Sridhar S; Gerstner Center for Cancer Diagnostics Broad Institute Cambridge Massachusetts USA., Blewett T; Gerstner Center for Cancer Diagnostics Broad Institute Cambridge Massachusetts USA., Cheng J; Gerstner Center for Cancer Diagnostics Broad Institute Cambridge Massachusetts USA., Dahi PB; Department of Medicine, Adult Bone Marrow Transplant Service Memorial Sloan-Kettering Cancer Center New York City New York USA., Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas USA., Joyce RM; Department of Hematologic Malignancy Beth Israel Deaconess Medical Center Boston Massachusetts USA., Chen YB; Bone Marrow Transplantation Program Massachusetts General Hospital Boston Massachusetts USA., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA., Armand P; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA., Murakami M; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA., Adalsteinsson VA; Gerstner Center for Cancer Diagnostics Broad Institute Cambridge Massachusetts USA.
Publikováno v:
HemaSphere [Hemasphere] 2024 Apr 01; Vol. 8 (4), pp. e47. Date of Electronic Publication: 2024 Apr 01 (Print Publication: 2024).
Autor:
Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA. Reid_merryman@dfci.harvard.edu., Redd RA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman AS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Ahn IE; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Jacobsen ED; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Ng S; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Odejide OO; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Parry EM; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Isufi I; Hematology, Yale University School of Medicine, New Haven, CT, USA., Kline J; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA., Cohen JB; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA., Mehta-Shah N; Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA., Bartlett NL; Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA., Mei M; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA., Kuntz TM; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Wolff J; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, USA.
Publikováno v:
Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 185-198. Date of Electronic Publication: 2023 Oct 18.
Autor:
Ryan CE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Zon RL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Shouval R; Adult Bone Marrow Transplantation and Cellular Therapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, New York, USA., Kumar A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Sadrzadeh H; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA., Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Nayak L; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Chukwueke UN; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Frigault MJ; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA., Palomba ML; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Epstein-Peterson Z; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Publikováno v:
British journal of haematology [Br J Haematol] 2023 Dec; Vol. 203 (5), pp. 774-780. Date of Electronic Publication: 2023 Aug 16.
Autor:
Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Redd RA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA., Taranto E; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Ahmed G; Medical College of Wisconsin, Milwaukee, WI., Jeter E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., McHugh KM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Freedman AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jacobsen E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Ng SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Odejide OO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Parry EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jacene H; Department of Imaging/Radiology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA., Park H; Department of Imaging/Radiology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA., Dahi PB; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY., Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Joyce RM; Department of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA., Chen YB; Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, MA., Shipp MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2023 Sep 12; Vol. 7 (17), pp. 4748-4759.
Autor:
Merrill MH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Dahi PB; Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Redd RA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., McDonough MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Chen YB; Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA., DeFilipp Z; Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Odejide OO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Ng SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Kim AI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Nieto YL; Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX., Sauter CS; Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Shah GL; Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY., Zain JM; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jacobsen ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Blood [Blood] 2023 Aug 17; Vol. 142 (7), pp. 621-628.
Autor:
Merryman RW; Dana-Farber Cancer Institute., LaCasce AS; Dana-Farber Cancer Institute.
Publikováno v:
Blood [Blood] 2023 Jun 01; Vol. 141 (22), pp. 2666-2668.
Autor:
Zeman MN; Department of Radiology, Brigham and Women's Hospital, Boston, MA., Akin EA; Department of Radiology, Division of Nuclear Medicine, George Washington University, Medical Faculty Associates, Washington, DC., Merryman RW; Harvard Medical School, Boston, MA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA., Jacene HA; Department of Radiology, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; Department of Imaging, Dana-Farber Cancer Institute, Boston, MA. Electronic address: hjacene@partners.org.
Publikováno v:
Seminars in nuclear medicine [Semin Nucl Med] 2023 May; Vol. 53 (3), pp. 371-388. Date of Electronic Publication: 2022 Nov 12.
Autor:
Merryman RW; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Michaud L; Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Mondello P; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medicine, New York, NY, USA., Park H; Department of Imaging, Dana-Farber Cancer Institute/Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA., Spilberg G; Department of Imaging, Dana-Farber Cancer Institute/Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA., Robertson M; Department of Imaging, Dana-Farber Cancer Institute/Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA., Taranto E; Division of Hematology and Oncology, Hospital of the University of Pennsylvania., Ahmed G; Medical College of Wisconsin, Milwaukee, WI, USA., Chase M; Divisions of Hematology and Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Jeter E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Ahn IE; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Brown JR; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Crombie J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Davids MS; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Fisher DC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Jacobsen E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Jacobson CA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Kim AI; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., LaCasce AS; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Ng SY; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Odejide OO; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Parry EM; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Salles G; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medicine, New York, NY, USA., Zelenetz AD; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medicine, New York, NY, USA., Armand P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Schöder H; Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jacene H; Department of Imaging, Dana-Farber Cancer Institute/Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Publikováno v:
HemaSphere [Hemasphere] 2023 Jan 24; Vol. 7 (2), pp. e826. Date of Electronic Publication: 2023 Jan 24 (Print Publication: 2023).
Autor:
Taranto E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Redd R; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Jeter E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., McHugh K; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Crombie JL; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Fisher DC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Jacobsen E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Jacobson CA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Kim AI; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., LaCasce AS; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Odejide OO; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Dahi PB; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Nieto Y; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Joyce RM; Department of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA., Chen YB; Hematopoietic Cell Therapy and Transplant Program, Massachusetts General Hospital, Boston, MA, USA., Bonjoc KC; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Chaudhry A; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Armand P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA., Merryman RW; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2912-2917. Date of Electronic Publication: 2022 Aug 07.
Autor:
Cliff ERS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. edwardr_cliff@dfci.harvard.edu.; Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Boston, MA, USA. edwardr_cliff@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. edwardr_cliff@dfci.harvard.edu., Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Publikováno v:
Nature medicine [Nat Med] 2022 Dec; Vol. 28 (12), pp. 2458-2459.